Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Fitzgerald (Vancouver, Canada), P. O'Byrne (Hamilton, Canada), E. Bateman (Cape Town, South Africa), P. Barnes (London, United Kingdom), N. Zhong (Guangzhou, China), V. Alagappan (Gaithersburg, United States of America), G. Whelan (Gaithersburg, United States of America), R. Lamarca (Barcelona, Spain), M. Puu (Gothenburg, Sweden), H. Reddel (Sydney, Australia). Number needed to treat (NNT) to have an additional patient free from a severe or moderate/severe exacerbation: post-hoc analysis of SYGMA 1 in mild asthma. 3716

Member's Comments

No comment yet.

Related content which might interest you: Number needed to treat (NNT) with budesonide/formoterol to avoid one COPD exacerbation, with cost analysis of treatment Source: Eur Respir J 2004; 24: Suppl. 48, 540s Year: 2004 Estimating the number of patients’ needed to treat (NNT) with indacaterol/glycopyrronium to prevent COPD exacerbations: Results from the FLAME study Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD Year: 2017 Late Breaking Abstract - Risk of a severe exacerbation following higher reliever use: post-hoc analysis of SYGMA 1 in mild asthma Source: International Congress 2018 – Variant forms of asthma Year: 2018 Number needed to treat (NNT) to prevent one exacerbation per year with omalizumab (OMA) In children with inadequately controlled allergic (IgE-mediated) asthma Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 Two versus three months rehabilitation with the same number of sessions in patients with moderate to severe COPD: analysis of the results Source: Eur Respir J 2004; 24: Suppl. 48, 244s Year: 2004 Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) versus open-label tiotropium (Tio) in COPD patients: Post hoc analysis from SHINE and SPARK studies Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Indacaterol/glycopyrronium (IND/GLY) delays clinically important deterioration (CID) versus salmeterol/fluticasone (SFC) in symptomatic COPD patients: LANTERN/ILLUMINATE pooled analysis Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Effect of high extrafine strength (HS) ICS-containing triple therapy on exacerbations in patients with severe asthma and persistent airflow limitation: Post-hoc analysis of the TRIGGER study Source: International Congress 2019 – Novel findings from asthma clinical trials Year: 2019 Revefenacin (REV) improves health status and dyspnea regardless of baseline symptom status in chronic obstructive pulmonary disease (COPD): a post hoc analysis of phase 3 trials Source: Virtual Congress 2020 – COPD : inhaled corticosteroids, bronchodilators and eosinophils Year: 2020 Clinical characteristics and outcomes of elderly patients with COPD: TIOSPIR® post-hoc analysis Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 LATE-BREAKING ABSTRACT: Indacaterol/glycopyrronium (IND/GLY) reduces the risk of exacerbations versus salmeterol/fluticasone (SFC) in moderate-to-very severe COPD patients irrespective of prior ICS/LABA/LAMA therapy: The FLAME study Source: International Congress 2016 – Novel strategies on COPD and asthma management Year: 2016 Number needed to treat: enigmatic results for exacerbations in COPD Source: Eur Respir J 2016; 47: 353-354 Year: 2016 Number needed to treat: enigmatic results for exacerbations in COPD Source: Eur Respir J 2016; 47: 354-355 Year: 2016 Number needed to treat: enigmatic results for exacerbations in COPD Source: Eur Respir J 2015; 45: 875-878 Year: 2015 Analysis of causes and quality of patients‘ treatment with often severe asthma exacerbations Source: Eur Respir J 2007; 30: Suppl. 51, 72s Year: 2007 Is the asthma control questionnaire (ACQ) usefull during acute moderate to severe (AMS) asthma exacerbations (AE)? Source: Eur Respir J 2004; 24: Suppl. 48, 591s Year: 2004 Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3, placebo (PBO)-controlled trials Source: International Congress 2016 – Asthma management Year: 2016 Descriptive analysis of patients admitted due to COPD exacerbation (COPDE) and COPD-pneumonia. Source: Virtual Congress 2020 – COPD phenotypes Year: 2020 COPD in the time of COVID-19: an analysis of acute exacerbations and reported behavioural changes in patients with COPD Source: ERJ Open Res, 7 (1) 00718-2020; 10.1183/23120541.00718-2020 Year: 2021